This animation created with cryo-EM structures depicts the pathway of the CRISPR Cas9 enzyme as it cuts DNA for gene editing. Animation courtesy of Xing Zhu, Miljan Simonovic and Sriram Subramaniam.

FREDERICK, Md. -- CRISPR is one of the most widely used technologies in the nascent quest to edit the human genome, and the precision “instrument” that makes it so effective is Cas9, a programmable enzyme harnessed from bacterial cells that cuts DNA strands at specific targets and replaces one gene with another.

David Pan watches the Vaccine, Immunity, and Cancer Program’s robot that performs automated testing for anti-HPV antibodies.

FREDERICK, Md. -- Ligia Pinto, Ph.D., sees science as a way to change lives and help people in need—and that is precisely what a study recently co-authored by her team at the Frederick National Laboratory for Cancer Research and collaborators at the H. Lee Moffitt Cancer Center and Research Institute and Weill Cornell Medicine holds promise to do.

HIV image. Photo courtesy National Institute of Allergy and Infectious Diseases.

FREDERICK, Md. -- Recent scientific papers co-authored by researchers at the Frederick National Laboratory for Cancer Research present novel discoveries about HIV and one similar infection from three fields of inquiry about the virus, all with the potential to further discoveries leading to prevention or treatment of HIV infection.

Ethan Dmitrovsky with Hood College symposium attendees.

FREDERICK, Md. – Leading experts in the imaging science and cancer biology field convened at Hood College June 21-23 for an in-depth look at the potential of new imaging technologies to transform their work. The Imaging Science and Cancer Biology Symposium, sponsored by Hood College and Leidos Biomedical Research, Inc. featured presentations exploring advances in understanding the mechanisms altering cancer cell signaling—as recently enabled by advanced imaging tools.

Tumor tissue will undergo testing for changes in more than 160 genes. If a patient's tumor has a genetic change that matches one targeted by a drug used in the trial, the patient may be eligible to join the treatment arm targeting that genetic change.

FREDERICK, Md. -- The National Cancer Institute–Children’s Oncology Group trial known as Pediatric MATCH (Molecular Analysis for Therapy Choice) trial launched in 2017, with significant operations and technical support from the Frederick National Laboratory for Cancer Research. Focusing on patients aged 1–21, Pediatric MATCH seeks to determine whether precision medicines that are designed to treat specific cancers with certain mutations can also treat other cancers with the same mutations.

NHP Models- Medicine, Simian Immunodeficiency Virus (SIV), Simian/Human Immunodeficiency Virus (SHIV), FNL SHIVs, FNL Barcoded SIV, Analysis, Study Design

FREDERICK, Md. -- Scientists at the Frederick National Laboratory for Cancer Research, the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center, and a team of collaborators have filled a gap in HIV research by developing 38 new simian/human immunodeficiency viruses (SHIVs) for prevention and treatment studies. The viruses are available to the scientific community through the national laboratory’s AIDS and Cancer Virus Program (ACVP).

Stock image of blood in a test tube

FREDERICK, Md. – Tissue biopsies are currently the norm for detecting and obtaining information about cancer. But this type of biopsy can be invasive, and not every patient can have one performed due to the location of their tumor or other health factors.   

Chicago skyline

CHICAGO – Frederick National Laboratory researchers will present their work across a range of cancer research topics including genomics, precision medicine, and molecular characterization at the annual meeting of the world’s leading clinical oncology organization.

The 2019 ASCO Annual Meeting in Chicago is expected to bring together more than 32,000 oncology professionals from around the globe. Each year, the conference features leading cancer experts who share the latest clinical cancer research affecting patient care. 

Frederick County Executive Jan Gardner speaks at the 2018 Technology Showcase at the Frederick National Laboratory. Photo by Richard Frederickson, staff photographer.

FREDERICK, Md. -- Next month, the annual Technology Showcase will return to the Frederick National Laboratory for Cancer Research. The event attracts research innovators and business professionals who wish to learn about advanced technologies being developed at the National Cancer Institute (NCI) and Frederick National Laboratory (FNL). 

More than 300 NCI technologies are currently available for licensing or collaboration leading to commercialization. The 2019 Technology Showcase aims to bring more visibility to external researchers for these opportunities at the NCI and FNL. 

Illustration of nanotechnology-based drug products, leukocytes, platelets, and complement.

UPDATE: This service is no longer being offered as part of the Technical Service Program, but it is still available through a contractor Cooperative Research and Development Agreement (cCRADA).